Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

Neuro-Oncology

Volumn 20, Issue 6, 2018, Pages 838-847

  Gan, Hui K ^a,b   Reardon, David A ^c   Lassman, Andrew B ^d   Merrell, Ryan ^e   Van Den Bent, Martin ^f   Butowski, Nicholas ^g   Lwin, Zarnie ^h   Wheeler, Helen ⁱ   Fichtel, Lisa ^j   Scott, Andrew M ^a,b   Gomez, Erica J ^k   Fischer, Judee ^k   Mandich, Helen ^k   Xiong, Hao ^k   Lee, Ho Jin ^k   Munasinghe, Wijith P ^k   Roberts Rapp, Lisa A ^k   Ansell, Peter J ^k   Holen, Kyle D ^k   Kumthekar, Priya ^l  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Department of Medicine   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ ROYAL NORTH SHORE HOSPITAL   (Australia)

^j South Texas Accelerated Research Therapeutics   (United States)

^k ABBVIE INC   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

antibody drug conjugate; depatux m; EGFR; phase 1; recurrent glioblastoma

Indexed keywords

DEPATUXIZUMAB MAFODOTIN; GAMMA GLUTAMYLTRANSFERASE; TEMOZOLOMIDE; ABT-414; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BACKACHE; BLURRED VISION; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORNEA DISEASE; CORNEAL DEPOSIT; COUGHING; DEHYDRATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE PAIN; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; INTRAOCULAR FOREIGN BODY; KERATITIS; MALE; MENINGITIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OPTIC NERVE DISEASE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PROGRESSION FREE SURVIVAL; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; BRAIN TUMOR; CLINICAL TRIAL; FOLLOW UP; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SAFETY; SURVIVAL RATE; TISSUE DISTRIBUTION; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOCONJUGATES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROGNOSIS; SAFETY; SURVIVAL RATE; TEMOZOLOMIDE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 85047772677     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nox202     Document Type: Article

References (26)

1. Brennan CW, Verhaak RG, McKenna A, et al; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
2. Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011;80(2):347-353.
3. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268-1274.
4. Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20(9):1596-1603.
5. Weller M, Butowski N, Tran D, et al. ACT IV: An international, doubleblind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIIIexpressing glioblastoma. Neuro Oncol. 2016;18(suppl 6):vi17-vi18.
6. Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012;12(3):197-209.
7. Reilly EB, Phillips AC, Buchanan FG, et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol Cancer Ther. 2015;14(5):1141-1151.
8. Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016;15(4):661-669.
9. Gan HK, Burgess AW, Clayton AH, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 2012;72(12):2924-2930.
10. Jungbluth AA, Stockert E, Huang HJ, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 2003;100(2):639-644.
11. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A. 2007;104(10):4071-4076.
12. Gan HK, Burge ME, Solomon BJ, et al. A phase I and biodistribution study of ABT-806i, an 111indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806. J Clin Oncol. 2013;31(suppl; abstr 2520).
13. Gan HK, Fichtel L, Lassman A, et al. A Phase 1 study evaluating ABT-414 with concurrent radiotherapy (RT) and temozolomide (TMZ) in glioblastoma (GBM). Presented at Society for Neuro-Oncology, November 13-16, 2014; Miami, Florida. 2014.
14. Reardon DA, Lassman AB, van den Bent M, et al. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol. 2017;19(7):965-975.
15. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med. 1995;14(11):1149-1161.
16. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics. 1996;52(2):673-684.
17. Piantadosi S, Fisher JD, Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol. 1998;41(6):429-436.
18. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
19. Thompson JA, Forero-Torres A, Heath EI, et al. The effect of SGN-75, a novel antibody-drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): a phase I study. J Clin Oncol. 2011;29(suppl; abstr 3071).
20. Fathi AT, Chen R, Trippett TM, et al. Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood. 2014;124(21):963.
21. Thompson JA, Motzer R, Molina AM, et al. Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). J Clin Oncol. 2015;33(suppl; abstr 2503).
22. Hopen G, Mondino BJ, Johnson BL, Chervenick PA. Corneal toxicity with systemic cytarabine. Am J Ophthalmol. 1981;91(4):500-504.
23. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol. 2013;15(1):4-27.
24. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17(9):2762-2771.
25. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-953.
26. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212-3218.